Business
Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and provides 2026 guidance
FY 2025 sales growth of 10.9% at CER1, or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1%1), Rare Disease (102.5%1) and Neuroscience (9.7%1); Somatuline® sales growth of 4.3%1, with all other products, excluding Somatuline, achieving double-digit sales growth of 14.2%1FY 2025 core operating income of €1,294m, growing by 16.7% as reported, with a core operating margin of 35.2% of total sales, increasing by 2.6 points2025 continued pipeline expansion, driven by
About this update from Ipsen Sa
[{"type":"image","alt":"Ipsen Pharma","displaySize":"","headline":null,"caption":"Ipsen Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/e6eb628cc0e353381e6b738c556a0e31"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/89RavcsKEHEdDt270X336Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e6eb628cc0e353381e6b738c556a0e31","width":300,"height":157}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"FY 2025 sales growth of 10.9% at CER1, or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1%1), Rare Disease (102.5%1) and Neuroscience (9.7%1); Somatuline® sales growth of 4.3%1, with all other products, excluding Somatuline, achieving double-digit sales growth of 14.2%1","length":305,"tagName":"p"}]},{"val":[{"type":"text","content":"FY 2025 core operating income of €1,294m, growing by 16.7% as reported, with a core operating margin of 35.2% of total sales, increasing by 2.6 points","length":155,"tagName":"p"}]},{"val":[{"type":"text","content":"2025 continued pipeline expansion, driven by significant regulatory and clinical milestones, integration of multiple preclinical assets with global rights and innovative approaches, and a mid-stage candidate from the acquisition of ImCheck Therapeutics","length":252,"tagName":"p"}]},{"val":[{"type":"text","content":"Five major regulatory and clinical milestones expected in 2026, in addition to the full data readout for IPN10200 in an aesthetics indication","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"Financial guidance2 for 2026 including total sales growth greater than 13.0%3 at CER, assuming an acceleration of our portfolio excluding Somatuline as well as the growth of Somatuline due to generic lanreotide production challenges, and core operating margin greater than 35.0% of total sales","length":293,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1146,"olType":false},{"type":"text","content":"PARIS, FRANCE, 12 February 2026 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the full year (FY) 2025 and for the fourth quarter of 2025.","length":220,"tagName":"p"},{"type":"table","headerItems":[],"item...